(VIANEWS) – ACOMO (ACOMO.AS), SANOFI (SAN.PA), HOME INVEST BE. (HOMI.BR) are the highest payout ratio stocks on this list.
We have collected information concerning stocks with the highest payout ratio as yet. The payout ratio in itself isn’t a promise of good investment but it’s an indicator of whether dividends are being paid and how the company chooses to issue them.
When investigating a potential investment, the dividend payout ratio is a good statistic to know so here are a few stocks with an above 30% percent payout ratio.
1. ACOMO (ACOMO.AS)
56.76% Payout Ratio
Acomo N.V., together with its subsidiaries, engages in sourcing, trading, processing, packaging, and distributing conventional and organic food ingredients and solutions for the food and beverage industry worldwide. It operates through five segments: Spices and Nuts, Edible Seeds, Organic Ingredients, Tea, and Food Solutions. The Spices and Nuts segment provides tropical products, including pepper, nutmeg, desiccated coconut, shelled and unshelled nuts, dried fruits, dehydrated vegetables, herbs, rice crackers, and snack products. Its Edible Seeds segment trades, processes, and distributes edible seeds, such as poppy, sesame, pumpkin, and flax, as well as sunflower seeds comprising in-kernel and shelled for the snack and retail industries; birdseeds for wildlife; and edible seeds to bakery, spice, and confectionery industries. The Organic Ingredients segment provides a range of organic food products and ingredients in various categories, including cocoa, coffee, fruit and vegetables, edible seeds, nuts and dried fruits, oils, and premium juice products. Its Tea segment trades, processes, and distributes through warehouses and blending facilities; and monitors and analyzes market development, and shares insight to customers to meet traditional consumer preferences, which include novel appetites for specialty tea. The Food Solutions segment produces and supplies culinary and functional ingredients, plant-based solutions, wet and dry blends, and spice mixes to food companies; and provides product development, manufacturing, packaging, distribution, and inventory management services. The company was formerly known as Amsterdam Commodities N.V. and changed its name to Acomo N.V. in June 2022. Acomo N.V. was founded in 1908 and is based in Rotterdam, the Netherlands.
Earnings Per Share
As for profitability, ACOMO has a trailing twelve months EPS of €1.85.
PE Ratio
ACOMO has a trailing twelve months price to earnings ratio of 12.11. Meaning, the purchaser of the share is investing €12.11 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.08%.
Sales Growth
ACOMO’s sales growth for the current quarter is 0.8%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Apr 25, 2023, the estimated forward annual dividend rate is 1.25 and the estimated forward annual dividend yield is 5.59%.
Volume
Today’s last reported volume for ACOMO is 4722 which is 79.19% below its average volume of 22693.
Moving Average
ACOMO’s worth is higher than its 50-day moving average of €21.87 and way above its 200-day moving average of €20.26.
More news about ACOMO.
2. SANOFI (SAN.PA)
50.08% Payout Ratio
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.51.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 15.28. Meaning, the purchaser of the share is investing €15.28 for every euro of annual earnings.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 3.56 and the estimated forward annual dividend yield is 3.59%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is a negative 5.2% and a negative 5.6%, respectively.
More news about SANOFI.
3. HOME INVEST BE. (HOMI.BR)
30.83% Payout Ratio
Home Invest Belgium S.A. operates as a real estate investment company in Belgium. It primarily invests in residential properties. As of December 31, 2008, the company's real estate portfolio consisted of 992 rental units with a total rentable space of approximately 111,091 square meters. The company was formerly known as Home Invest and changed its name to Home Invest Belgium S.A. in May 1999. Home Invest Belgium S.A. was founded in 1980 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, HOME INVEST BE. has a trailing twelve months EPS of €3.22.
PE Ratio
HOME INVEST BE. has a trailing twelve months price to earnings ratio of 6.2. Meaning, the purchaser of the share is investing €6.2 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.2%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on May 8, 2023, the estimated forward annual dividend rate is 1 and the estimated forward annual dividend yield is 5.03%.
Volume
Today’s last reported volume for HOME INVEST BE. is 976 which is 86.27% below its average volume of 7111.
More news about HOME INVEST BE..
4. CRCAM NORM.SEINE (CCN.PA)
30.05% Payout Ratio
Caisse Régionale de Crédit Agricole Mutuel de Normandie-Seine Société cooperativ offers various banking products and services to individuals, professionals, farmers, associations, and companies in France. It provides savings accounts; credit products; property, personal, life, and pension insurance products; factoring; brokerage; investment banking; asset management; real estate promotion services; specialized funding products; and various loans. The company was incorporated in 2000 and is headquartered in Bois Guillaume, France. Caisse Régionale de Crédit Agricole Mutuel de Normandie-Seine Société coopérativ is a subsidiary of Crédit Agricole S.A.
Earnings Per Share
As for profitability, CRCAM NORM.SEINE has a trailing twelve months EPS of €13.46.
PE Ratio
CRCAM NORM.SEINE has a trailing twelve months price to earnings ratio of 5.72. Meaning, the purchaser of the share is investing €5.72 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.01%.
Volume
Today’s last reported volume for CRCAM NORM.SEINE is 429 which is 27.29% above its average volume of 337.
More news about CRCAM NORM.SEINE.
